aTyr Pharma, Inc. (ATYR) Misses Q3 EPS by 9c

aTyr Pharma, Inc. (NASDAQ: ATYR) reported Q3 EPS of ($0.26), $0.09 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $190 thousand versus the consensus estimate of $1.33 million.

For earnings history and earnings-related data on aTyr Pharma, Inc. (ATYR) click here.

You May Also Be Interested In

• Top Wealth Group expects net profit to double in fiscal 2026
• Maxim Group Upgrades Nvni Group Ltd. (NVNI) to Buy
• Largo shifts focus to high-margin vanadium and copper-PGM products